These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Subscribe To Our Newsletter & Stay Updated
